**Supporting Information**

**Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer**

1Yoon Soo Hah, 2Jong Soo Lee, 2Koon Ho Rha, 2Sung Joon Hong, 3Byung Ha Chung, 3\*Kyo Chul Koo

1Department of Urology, Daegu Catholic University Medical Center, Daegu, Republic of Korea

2Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

3Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

**\*Corresponding author:** Kyo Chul Koo, MD, PhD

Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, Republic of Korea, 135-720.

Tel: +82-2-2019-3470

Fax: +82-2-3462-8887

E-mail: gckoo@yuhs.ac

Supplementary table. Treatments administered for castration-resistant prostate cancer.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Overall**  **(n = 295)** | **Time to PSA nadir** | | |  | **Time to CRPC progression** | | |
| **<6 months**  **(n = 218)** | **≥6 months**  **(n = 77)** | ***p*** |  | **≥12 months**  **(n = 237)** | **<12 months**  **(n = 58)** | ***p*** |
| Docetaxel |  |  |  |  |  |  |  |  |
| N | 264 (89.5%) | 196 (89.9%) | 68 (88.3%) | 0.670 |  | 216 (91.1%) | 48 (82.8%) | 0.091 |
| No. cycles | 4.0 (3.0 – 7.5) | 5.0 (3.0 – 9.5) | 3.0 (2.5 – 5.0) | 0.054 |  | 5.0 (3.0 – 8.5) | 3.0 (2.5 – 5.5) | 0.028 |
| ARAT agent use | 201 (68.1%) | 155 (71.1%) | 46 (59.7%) | 0.087 |  | 158 (66.7%) | 43 (74.1%) | 0.346 |
| Pre-chemotherapy | 33 (11.2%) | 20 (9.2%) | 13 (16.9%) | 0.090 |  | 28 (11.8%) | 5 (8.6%) | 0.643 |
| Abiraterone | 14 (4.7%) | 8 (3.7%) | 6 (7.8%) | 0.208 |  | 9 (3.8%) | 5 (8.6%) | 0.161 |
| Enzalutamide | 27 (9.2%) | 17 (7.8%) | 10 (13.0%) | 0.175 |  | 23 (9.7%) | 4 (6.9%) | 0.619 |
| Post-chemotherapy | 154 (52.2%) | 120 (55.0%) | 34 (44.2%) | 0.112 |  | 126 (53.2%) | 28 (48.3%) | 0.559 |
| Abiraterone | 38 (12.9%) | 24 (11.0%) | 14 (18.2%) | 0.116 |  | 33 (13.9%) | 5 (8.6%) | 0.382 |
| Enzalutamide | 134 (45.4%) | 102 (46.8%) | 32 (41.6%) | 0.506 |  | 111 (46.8%) | 23 (39.7%) | 0.378 |
| Cabazitaxel | 4 (1.4%) | 2 (0.9%) | 2 (2.6%) | 0.280 |  | 3 (1.3%) | 1 (1.7%) | 0.586 |
| 233Radium | 2 (0.7%) | 1 (0.5%) | 1 (1.3%) | 0.455 |  | 2 (0.8%) | 0 (0.0%) | 1.000 |
| Clinical trials | 73 (24.7%) | 57 (26.1%) | 16 (20.8%) | 0.443 |  | 59 (24.9%) | 14 (24.1%) | 1.000 |

Data are median (interquartile range) and number (%)

ARAT, androgen receptor-axis targeted; PSA, prostate-specific antigen